University of Exeter: Exeter healthy ageing treatments company raises £2 million in latest seed funding round
Summary
SENISCAs discoveries in cell rejuvenation have a vast potential as they target a large set of age related diseases at their origin and thereby can profoundly impact todays treatment options. QantX invests in South West based companies that have global potential and SENISCA is a great example of the partnership between capital and talent that we seek to nurture.The \xa32.15m of cash funds raised supplements the recent award of a \xa3180,000 grant from Innovate UK, the third non-dilutive funding grant that the company has been awarded since incorporation in 2020.SENISCAs innovation, which restores functional levels of RNA splicing factors (which are essential for cellular responses), takes old or senescent cells and effectively resets the cellular ageing clock. This combination of new equity and grant funding allows SENISCA to progress its anti-ageing compounds through to the next phase of ex vivo laboratory tests, as well as expand its management team. The next seed round is scheduled for early 2023 and will seek to raise more than \xa35 million.Kirsty Semple, Chief Executive Officer, said: This latest investment is cementing our place as a global leader in developing medicines to target the causes of ageing. We are developing a program of small molecule and targeted oligonucleotide therapeutics, together with biomarker discovery, to persuade cells back to a more youthful and functional state.